Barrons.com15d agobullish
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.Ionis Pharmaceuticals wins regulatory clearance for its quarterly injection, Zanvastro, in Alexander disease. Analysts are focused elsewhere.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
66last 24h
973last 7d
109● bullish (7d)
123● bearish (7d)
212publishers
MT Newswires24d agobullish
Veeva's Vault CRM Wins Reinforce Market-Leader Status Ahead of Earnings, Truist SaysVeeva Systems' (VEEV) Vault CRM has cemented its position as the clear market leader in life science
Investing.com37d agobullish
Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuationInvesting.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts.
Zacks52d agobullish
Biogen's Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance RaisedBiogen tops Q2 earnings and revenue estimates as growth drugs fuel sales, offset MS declines, and support a higher 2026 revenue and EPS outlook.
Investing.com68d agobullish
Truist upgrades Biogen to Buy on Alzheimer’s, pipeline optimism ahead of key dataInvesting.com -- Truist Securities upgraded Biogen to Buy from Hold and raised its price target to $235 from $190, citing growing confidence in the company’s Alzheimer’s and immunology pipeline ahead of several major clinical data readouts over the next two years.